Organisation paid for research Program year 2025 Source: CMS Open Payments

Precision Comprehensive Clinical Research Solutions

Neither a doctor nor a teaching hospital

Research payments

$1,857,410

337 payments

Through program year 2025, Precision Comprehensive Clinical Research Solutions is reported as receiving $1,857,410 in research payments, across 337 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$81,079	17
2024	Research	$128,550	22
2023	Research	$127,918	39
2022	Research	$283,989	22
2021	Research	$442,626	92
2020	Research	$560,060	102
2019	Research	$233,188	43

Breakdown

Who paid Research payments · program years 2019–2025

GlaxoSmithKline, LLC. $662,436 119 payments
AbbVie, Inc. $600,255 95 payments
Amgen Inc. $204,346 13 payments
Novartis Pharmaceuticals Corporation $100,034 4 payments
E.R. Squibb & Sons, L.L.C. $89,331 8 payments
Horizon Therapeutics plc $66,366 4 payments
Sun Pharmaceutical Industries Inc. $44,701 36 payments
Daiichi Sankyo Company LTD $31,747 9 payments
Sanofi US Services Inc. $25,650 24 payments
Daiichi Sankyo Inc. $22,903 19 payments

Studies the money was for Research payments · program years 2019–2025

A 52-Week, Phase 3, Multicentre, Randomised, Double Blind, Efficacy An $255,083 66 payments
A 24-Week, Phase 3, Multicentre, Randomised, Double-Blind, Efficacy An $227,194 29 payments
M15-998 $215,387 17 payments
A Multi-Centre Long-Term Extension Study to Assess the Safety and Effi $125,093 16 payments
M16-011 $124,843 29 payments
Ph4 Otezla in oligoarticular PsA (FOREMOST)/KEG $113,111 2 payments
A Randomized, Parallel Group, Double Blind, Placebo Controlled Multicenter Phase III Trial to Investigate the Efficacy and Safety of Secukinumab 300 MG Administered Subcutaneously Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patien $89,725 2 payments
M15-572 $82,284 16 payments
Phase III Study -SLE #2 - A Phase 3, Randomized, Double-Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants with Active Systemic Lupus Erythematosus (SLE) (POETYK SLE-2) $77,021 2 payments
A Phase 3, Randomized, Double-Blind Study Comparing Risankizumab to Placebo in Subjects with Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or intolerance to Biologic Therapy(ies) (KEEPsAKE 2) $76,745 10 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.